SELANK
Solid research foundation with human clinical data backing both anxiety reduction and cognitive benefits. One of the better-studied synthetic peptides in the nootropic space, though most research originates from Russian institutions.
Primarily investigated by neuropsychiatric researchers studying anxiety disorders and cognitive enhancement, with particular focus in Eastern European academic institutions.
Since Mar 2024
15 total, 6 human
What is SELANK?
Originally developed by Russian researchers as a modified version of tuftsin, this heptapeptide has garnered attention for its dual-action profile targeting both anxiety and cognitive performance. Unlike many nootropics that focus solely on cognitive enhancement, Selank appears to calm the mind while simultaneously sharpening focus. Research teams studying stress-related cognitive decline have shown particular interest in its potential therapeutic applications.
The peptide works by fine-tuning three major neurotransmitter pathways—GABA for relaxation, serotonin for mood stability, and dopamine for motivation and focus—while simultaneously boosting brain-derived neurotrophic factor (BDNF) production. Think of it as adjusting multiple dials on your brain's control panel at once: turning down the anxiety volume while turning up cognitive clarity and neuroplasticity. This multi-target approach may explain why users report feeling both calmer and more mentally sharp.
What the Research Shows
Decent evidence base with 6 human studies among 15 total publications, though geographic concentration of research in Russia may limit broader validation.
Notable Studies
Medvedev VE, Tereshchenko ON, Kost NV et al. · Zh Nevrol Psikhiatr Im S S Korsakova (2015)
RCT · n=70
Zozulia AA, Neznamov GG, Siuniakov TS et al. · Zh Nevrol Psikhiatr Im S S Korsakova (2008)
RCT · n=62
Medvedev VE, Tereshchenko ON, Israelian AIu et al. · Zh Nevrol Psikhiatr Im S S Korsakova (2014)
RCT · n=60
Panikratova YR, Lebedeva IS, Sokolov OY et al. · Dokl Biol Sci (2020)
Cohort · n=52
Uchakina ON, Uchakin PN, Miasoedov NF et al. · Zh Nevrol Psikhiatr Im S S Korsakova (2008)
Case Series · 14 days
Reported Benefits
Regulatory Status
Last verified: Feb 2026
Related Peptides
This information is for research purposes only and does not constitute medical advice. Always consult a licensed physician before using any peptides.